{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T08:48:15Z","timestamp":1791103695924,"version":"4.1.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"24","license":[{"start":{"date-parts":[[2011,1,31]],"date-time":"2011-01-31T00:00:00Z","timestamp":1296432000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2011,1,31]],"date-time":"2011-01-31T00:00:00Z","timestamp":1296432000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Oncogene"],"published-print":{"date-parts":[[2011,6,16]]},"DOI":"10.1038\/onc.2011.3","type":"journal-article","created":{"date-parts":[[2011,1,31]],"date-time":"2011-01-31T11:19:04Z","timestamp":1296472744000},"page":"2789-2797","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Combined effects of novel heat shock protein 90 inhibitor NVP-AUY922 and nilotinib in a random mutagenesis screen"],"prefix":"10.1038","volume":"30","author":[{"given":"T","family":"Tauchi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Okabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E","family":"Ashihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T","family":"Maekawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K","family":"Ohyashiki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2011,1,31]]},"reference":[{"key":"BFonc20113_CR1","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1016\/S0092-8674(03)00190-9","volume":"112","author":"M Azam","year":"2003","unstructured":"Azam M, Latek R, Daley GQ . (2003). Mechanisms of autoinhibition and STI-571\/imatinib resistance revealed by mutagenesis of BCR-ABL. Cell 112: 831\u2013843.","journal-title":"Cell"},{"key":"BFonc20113_CR2","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1038\/nbt1328","volume":"25","author":"M Bantscheff","year":"2007","unstructured":"Bantscheff M, Eberhard D, Abraham Y, Bastuck S, Boesche M, Hobson S et al. (2007). Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors. Nat Biotech 25: 1035\u20131044.","journal-title":"Nat Biotech"},{"key":"BFonc20113_CR3","doi-asserted-by":"publisher","first-page":"5426","DOI":"10.1182\/blood-2009-08-215939","volume":"114","author":"S Branford","year":"2009","unstructured":"Branford S, Melo JV, Hughes PT . (2009). Selecting optimal second-line tyrosine kinase inhibitor therapy for chronic myeloid leukemia patients after imatinib failure: does the BCR-ABL mutation status really matter? Blood 114: 5426\u20135435.","journal-title":"Blood"},{"key":"BFonc20113_CR4","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1021\/jm701018h","volume":"51","author":"PA Brough","year":"2008","unstructured":"Brough PA, Aherne W, Barril X, Borgogononi J, Boxall K, Cansfield JE et al. (2008). 4,5-Diarylisoxazole Hsp90 chaperone inhibitors: potential therapeutic agents for the treatment of cancer. J Med Chem 51: 196\u2013218.","journal-title":"J Med Chem"},{"key":"BFonc20113_CR5","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1016\/j.leukres.2007.11.008","volume":"32","author":"Y Deguchi","year":"2008","unstructured":"Deguchi Y, Kimura S, Ashihara E, Niwa T, Hodohara K, Fujiyama Y et al. (2008). Comparison of imatinib, dasatinib, nilotinib and INNO-406 in imatinib-resistant cell lines. Leuk Res 32: 980\u2013983.","journal-title":"Leuk Res"},{"key":"BFonc20113_CR6","doi-asserted-by":"publisher","first-page":"2850","DOI":"10.1158\/0008-5472.CAN-07-5256","volume":"68","author":"SA Eccles","year":"2008","unstructured":"Eccles SA, Massey A, Raynaud FI, Sharp SY, Box G, Valenti M et al. (2008). NVP-AUY922: a novel heat shock protein 90 inhibitor active against xenograft tumor growth, angiogenesis, and metastasis. Cancer Res 68: 2850\u20132860.","journal-title":"Cancer Res"},{"key":"BFonc20113_CR7","doi-asserted-by":"publisher","first-page":"4361","DOI":"10.1182\/blood-2009-05-221531","volume":"114","author":"RJ Garg","year":"2009","unstructured":"Garg RJ, Kantarjian H, O'Brien S, Quintas-Cardama A, Faderl S, Estrov Z et al. (2009). The use of nilotinib or dasatinib after failure to 2 prior tyrosine kinase inhibitors: long-term follow-up. Blood 114: 4361\u20134368.","journal-title":"Blood"},{"key":"BFonc20113_CR8","doi-asserted-by":"publisher","first-page":"3041","DOI":"10.1182\/blood-2002-05-1361","volume":"100","author":"ME Gorre","year":"2002","unstructured":"Gorre ME, Ellwood-Yen K, Chiosis G, Rosen N, Sawyers CL . (2002). BCR-ABL point mutants isolated from patients with imatinib mesylate-resistant chronic myeloid leukemia remain sensitive to inhibitors of the BCR-ABL chaperone heat shock protein 90. Blood 100: 3041\u20133044.","journal-title":"Blood"},{"key":"BFonc20113_CR9","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1182\/blood-2007-11-123950","volume":"112","author":"E Jabbour","year":"2008","unstructured":"Jabbour E, Kantarjian H, Jones D, Breeden M, Garcia-Manero G, O'Brien S et al. (2008). Characteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation following failure of imatinib mesylate therapy. Blood 112: 53\u201355.","journal-title":"Blood"},{"key":"BFonc20113_CR10","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1182\/blood.V97.7.1999","volume":"97","author":"Y Kano","year":"2001","unstructured":"Kano Y, Akutsu M, Tsunoda S, Mano H, Sato Y, Honma Y et al. (2001). In vitro cytotoxic effects of a tyrosine kinase inhibitor STI571 in combination with commonly used antileukemic agents. Blood 97: 1999\u20132007.","journal-title":"Blood"},{"key":"BFonc20113_CR11","doi-asserted-by":"publisher","first-page":"6322","DOI":"10.1182\/blood-2008-11-186817","volume":"113","author":"H Kantarjian","year":"2009","unstructured":"Kantarjian H, Cortes J, Kim D-W, Dorlhiac-Llacer P, Pasquini R, DiPersio J et al. (2009). Phase 3 study of dasatinib 140 mg once daily versus 70 mg twice daily in patients with chronic myeloid leukemia in accelerated phase resistant or intolerant to imatinib: 15-month median follow-up. Blood 113: 6322\u20136329.","journal-title":"Blood"},{"key":"BFonc20113_CR12","doi-asserted-by":"publisher","first-page":"2542","DOI":"10.1056\/NEJMoa055104","volume":"354","author":"H Kantarjian","year":"2006","unstructured":"Kantarjian H, Giles F, Wunderle L, Bhalla K, O'Brian S, Wassmann B et al. (2006). Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med 354: 2542\u20132551.","journal-title":"N Engl J Med"},{"key":"BFonc20113_CR13","doi-asserted-by":"publisher","first-page":"5143","DOI":"10.1182\/blood-2006-11-056028","volume":"109","author":"H Kantarjian","year":"2007","unstructured":"Kantarjian H, Pasquini R, Hamerschlak N, Rousselot P, Holowiecki P, Jootar S et al. (2007). Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: a randomized phase 2 trial. Blood 109: 5143\u20135150.","journal-title":"Blood"},{"key":"BFonc20113_CR14","doi-asserted-by":"publisher","first-page":"2332","DOI":"10.4049\/jimmunol.172.4.2332","volume":"172","author":"W Matsuyama","year":"2004","unstructured":"Matsuyama W, Wang L, Farrar WL, Faure M, Yoshimura T . (2004). Activation of discoidin domain receptor 1 isoform b with collagen up-regulates chemokine production in human macrophages: role of p38 mitogen-activated protein kinase and NF-kappa B. J Immunol 172: 2332\u20132340.","journal-title":"J Immunol"},{"key":"BFonc20113_CR15","doi-asserted-by":"publisher","first-page":"4179","DOI":"10.1038\/sj.onc.1210179","volume":"26","author":"K Nunoda","year":"2007","unstructured":"Nunoda K, Tauchi T, Takaku T, Okabe S, Akahane D, Sashida G et al. (2007). Identification and functional signature of genes regulated by structurally different ABL kinase inhibitors. Oncogene 26: 4179\u20134188.","journal-title":"Oncogene"},{"key":"BFonc20113_CR16","doi-asserted-by":"publisher","first-page":"2242","DOI":"10.1182\/blood-2007-03-066936","volume":"110","author":"T O'Hare","year":"2007","unstructured":"O'Hare T, Eide CA, Deininger MWN . (2007). Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia. Blood 110: 2242\u20132249.","journal-title":"Blood"},{"key":"BFonc20113_CR17","doi-asserted-by":"publisher","first-page":"2309","DOI":"10.1182\/blood-2007-02-073528","volume":"110","author":"O Ottmann","year":"2007","unstructured":"Ottmann O, Dombret H, Martinelli G, Simonsson B, Guilhot F, Larson RA et al. (2007). Dasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: interim results of a phase 2 study. Blood 110: 2309\u20132315.","journal-title":"Blood"},{"key":"BFonc20113_CR18","doi-asserted-by":"publisher","first-page":"5011","DOI":"10.1182\/blood-2006-01-015347","volume":"109","author":"A Ray","year":"2007","unstructured":"Ray A, Cowan-Jacob SW, Manley PW, Mestan J, Griffin JD . (2007). Identification of BCR-ABL point mutations conferring resistance to the Abl kinase inhibitor AMN107 (nilotinib) by a random mutagenesis study. Blood 109: 5011\u20135015.","journal-title":"Blood"},{"key":"BFonc20113_CR19","doi-asserted-by":"publisher","first-page":"4055","DOI":"10.1182\/blood-2007-07-102061","volume":"110","author":"U Rix","year":"2007","unstructured":"Rix U, Hantschel O, Dumberger G, Remsing Rix LL, Planyavsky M, Feenbach NV et al. (2007). Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets. Blood 110: 4055\u20134063.","journal-title":"Blood"},{"key":"BFonc20113_CR20","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1126\/science.1099480","volume":"305","author":"NP Shah","year":"2004","unstructured":"Shah NP, Tran C, Lee FY, Chen P, Norris D, Saywers CL . (2004). Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 305: 399\u2013401.","journal-title":"Science"},{"key":"BFonc20113_CR21","doi-asserted-by":"publisher","first-page":"1604","DOI":"10.1038\/leu.2008.111","volume":"22","author":"T Stuhmer","year":"2008","unstructured":"Stuhmer T, Zollinger A, Siegmund D, Chatterjee M, Grella E, Knop S et al. (2008). Signalling profile and antitumour activity of the novel Hsp90 inhibitor NVP-AUY922 in multiple myeloma. Leukemia 22: 1604\u20131612.","journal-title":"Leukemia"},{"key":"BFonc20113_CR22","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1084\/jem.179.1.167","volume":"179","author":"T Tauchi","year":"1994","unstructured":"Tauchi T, Boswell HS, Leibowitz D, Broxneyer HE . (1994). Coupling between p210bcr-abl and Shc and Grb2 adaptor proteins in hematopoietic cells permits growth factor receptor-independent link to ras activation pathway. J Exp Med 179: 167\u2013175.","journal-title":"J Exp Med"},{"key":"BFonc20113_CR23","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.ccr.2005.01.007","volume":"7","author":"E Weisberg","year":"2005","unstructured":"Weisberg E, Manley PW, Breitenstein W, Bruggen J, Cowan-Jacob SW, Ray A et al. (2005). Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell 7: 129\u2013141.","journal-title":"Cancer Cell"}],"container-title":["Oncogene"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/onc20113.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/onc20113","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/onc20113.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,21]],"date-time":"2022-03-21T18:07:49Z","timestamp":1647886069000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/onc20113"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,1,31]]},"references-count":23,"journal-issue":{"issue":"24","published-print":{"date-parts":[[2011,6,16]]}},"alternative-id":["BFonc20113"],"URL":"https:\/\/doi.org\/10.1038\/onc.2011.3","relation":{},"ISSN":["0950-9232","1476-5594"],"issn-type":[{"value":"0950-9232","type":"print"},{"value":"1476-5594","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,1,31]]},"assertion":[{"value":"10 February 2010","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 November 2010","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 January 2011","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 January 2011","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"TT receives research support from Novartis Pharma K.K.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}